Log in

NASDAQ:HOOK - Hookipa Pharma Stock Price, Forecast & News

$12.04
+0.04 (+0.33 %)
(As of 02/16/2020 02:49 PM ET)
Add
Today's Range
$12.00
Now: $12.04
$12.42
50-Day Range
$11.13
MA: $12.07
$13.80
52-Week Range
$6.06
Now: $12.04
$14.76
Volume51,688 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:HOOK
CUSIPN/A
CIKN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees56
Next Earnings Date2/18/2020 (Estimated)
OptionableNot Optionable

Receive HOOK News and Ratings via Email

Sign-up to receive the latest news and ratings for HOOK and its competitors with MarketBeat's FREE daily newsletter.


Hookipa Pharma (NASDAQ:HOOK) Frequently Asked Questions

What is Hookipa Pharma's stock symbol?

Hookipa Pharma trades on the NASDAQ under the ticker symbol "HOOK."

How were Hookipa Pharma's earnings last quarter?

Hookipa Pharma Inc (NASDAQ:HOOK) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.45) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.66) by $0.21. The business earned $2.04 million during the quarter, compared to analyst estimates of $2.35 million. View Hookipa Pharma's Earnings History.

When is Hookipa Pharma's next earnings date?

Hookipa Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for Hookipa Pharma.

What price target have analysts set for HOOK?

5 Wall Street analysts have issued 12 month price targets for Hookipa Pharma's shares. Their forecasts range from $15.00 to $23.00. On average, they expect Hookipa Pharma's stock price to reach $19.00 in the next year. This suggests a possible upside of 57.8% from the stock's current price. View Analyst Price Targets for Hookipa Pharma.

What is the consensus analysts' recommendation for Hookipa Pharma?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hookipa Pharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Hookipa Pharma.

Has Hookipa Pharma been receiving favorable news coverage?

News coverage about HOOK stock has trended neutral recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Hookipa Pharma earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Hookipa Pharma.

Are investors shorting Hookipa Pharma?

Hookipa Pharma saw a drop in short interest during the month of January. As of January 31st, there was short interest totalling 196,700 shares, a drop of 33.9% from the January 15th total of 297,700 shares. Based on an average trading volume of 105,200 shares, the short-interest ratio is currently 1.9 days. Currently, 1.7% of the company's shares are short sold. View Hookipa Pharma's Current Options Chain.

What other stocks do shareholders of Hookipa Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hookipa Pharma investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Pfizer (PFE), Exxon Mobil (XOM), Alector (ALEC), Kaleido Biosciences (KLDO), LogicBio Therapeutics (LOGC), Verizon Communications (VZ), Akero Therapeutics (AKRO) and Axsome Therapeutics (AXSM).

Who are Hookipa Pharma's key executives?

Hookipa Pharma's management team includes the folowing people:
  • Mr. Joern Aldag, Pres, CEO & Director (Age 60)
  • Mr. Daniel Pinschewer, Founder & Chief Scientific Officer (Age 44)
  • Dr. Reinhard Kandera, CFO & Director (Age 50)
  • Mr. Anders Lilja Ph.D., Sr. VP of Technical Devel. (Age 46)
  • Mrs. Nina Waibel, Communications & Investor Relations Mang.

When did Hookipa Pharma IPO?

(HOOK) raised $100 million in an IPO on Thursday, April 18th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Kempen was co-manager.

Who are Hookipa Pharma's major shareholders?

Hookipa Pharma's stock is owned by many different of retail and institutional investors. Top institutional investors include FMR LLC (2.27%), State Street Corp (0.43%), Bank of New York Mellon Corp (0.13%), Charles Schwab Investment Management Inc. (0.10%), UBS Group AG (0.06%) and Bank of America Corp DE (0.05%). Company insiders that own Hookipa Pharma stock include Anders Lilja, Bros Advisors Lp Baker, Igor Matushansky, Klaus Orlinger and Sofinnova Capital Vi Fcpr. View Institutional Ownership Trends for Hookipa Pharma.

Which major investors are selling Hookipa Pharma stock?

HOOK stock was sold by a variety of institutional investors in the last quarter, including FMR LLC and Bank of America Corp DE. Company insiders that have sold Hookipa Pharma company stock in the last year include Anders Lilja, Igor Matushansky and Klaus Orlinger. View Insider Buying and Selling for Hookipa Pharma.

Which major investors are buying Hookipa Pharma stock?

HOOK stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Charles Schwab Investment Management Inc., Bank of New York Mellon Corp, UBS Group AG, Barclays PLC and American International Group Inc.. Company insiders that have bought Hookipa Pharma stock in the last two years include Bros Advisors Lp Baker and Sofinnova Capital Vi Fcpr. View Insider Buying and Selling for Hookipa Pharma.

How do I buy shares of Hookipa Pharma?

Shares of HOOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Hookipa Pharma's stock price today?

One share of HOOK stock can currently be purchased for approximately $12.04.


MarketBeat Community Rating for Hookipa Pharma (NASDAQ HOOK)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  35 (Vote Outperform)
Underperform Votes:  33 (Vote Underperform)
Total Votes:  68
MarketBeat's community ratings are surveys of what our community members think about Hookipa Pharma and other stocks. Vote "Outperform" if you believe HOOK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HOOK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel